Clinical Trial Search

Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Primary: Post-operative Pain — 22; 30 milligram morphine equivalent

Primary: Composite Z-score of a Study-specific Neuropsychological Test Battery (NTB) Including Tests From Cogstate Battery, Letter Fluency Test and Category Fluency Test — 0.06…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 6; 0; 1 Participants

Primary: Progression-free Survival (PFS) — 27.7; 26.4 weeks — p=0.86

Primary: The Percentage of Subjects Who Tolerate at Least 300 mg (443 mg Cumulative) of Peanut Protein With no More Than Mild Symptoms at the Exit DBPCFC — 23; 5 Participants…

Primary: Mean Change From Baseline in the Number of Monthly Cumulative Headache Hours of Any Severity on Headache Days Relative to the 28-day Post-treatment Period Ending With…

Primary: Number of Participants With Clinically Significant Abnormality in Vital Signs — 23; 11; 34; 25 Participants

Primary: Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale — 60.6; 60.8 Percentage of participants — p=0.6750

Primary: Feasibility Defined as Proportion of Patients Willing to be Randomized to Either Intensive or Non-intensive Induction and Post Remission Chemotherapy — 3; 47 Participants

Primary: Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population — 16.7; 8.3; 9.1; 11.4 Percentage of participants (%)

Primary: Percentage of Subjects Who Have 75% or More Reduction in [Psoriasis Area-and-severity Index Score (PASI)] (PASI75) — 8; 0 Participants

Primary: Oral Intake in ml/kg — 9.7; 10.7 oral intake in ml/kg

Primary: Number of Participants With Treatment-related Adverse Events (AEs) — 7 Participants

Primary: Overall Response Rate (ORR) — 0 Participants